Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.27
0.111.08%
Pre-Market: 7:51 PM EDT
Comments
Loading...
NeoGenomics Analyst Ratings and Price Targets | NASDAQ:NEO | Benzinga
NeoGenomics Inc has a consensus price target of $19.08 based on the ratings of 15 analysts. The high is $26 issued by Craig-Hallum on May 1, 2024. The low is $15 issued by SVB Leerink on November 9, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, B of A Securities, and Needham on February 26, 2025, February 19, 2025, and February 19, 2025, respectively. With an average price target of $17.33 between Piper Sandler, B of A Securities, and Needham, there's an implied 68.78% upside for NeoGenomics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
B of A Securities
Needham
Goldman Sachs
Jefferies
1calculated from analyst ratings
Analyst Ratings for NeoGenomics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/26/2025 | Buy Now | 75.27% | Piper Sandler | David Westenberg59% | $21 → $18 | Maintains | Overweight | Get Alert |
| 02/19/2025 | Buy Now | 55.79% | B of A Securities | Derik De Bruin84% | $19 → $16 | Maintains | Neutral | Get Alert |
| 02/19/2025 | Buy Now | 75.27% | Needham | Mike Matson57% | $19 → $18 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | 75.27% | Goldman Sachs | Matthew Sykes66% | $20 → $18 | Maintains | Buy | Get Alert |
| 01/16/2025 | Buy Now | — | Benchmark | Bruce Jackson42% | — | Reiterates | Hold → Hold | Get Alert |
| 01/15/2025 | Buy Now | 85% | Needham | Mike Matson57% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | — | Benchmark | Bruce Jackson42% | — | Downgrade | Buy → Hold | Get Alert |
| 01/10/2025 | Buy Now | 85% | Needham | Mike Matson57% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 85% | B of A Securities | Derik De Bruin84% | $18 → $19 | Maintains | Neutral | Get Alert |
| 12/10/2024 | Buy Now | 114.22% | Jefferies | Tycho Peterson83% | → $22 | Initiates | → Buy | Get Alert |
| 11/06/2024 | Buy Now | 85% | Needham | Mike Matson57% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2024 | Buy Now | 85% | Needham | Mike Matson57% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 75.27% | Benchmark | Bruce Jackson42% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 85% | Stephens & Co. | Mason Carrico40% | $19 → $19 | Reiterates | Overweight → Overweight | Get Alert |
| 07/30/2024 | Buy Now | 75.27% | Benchmark | Bruce Jackson42% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 85% | Needham | Mike Matson57% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 104.48% | BTIG | Mark Massaro72% | $23 → $21 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 75.27% | Benchmark | Bruce Jackson42% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 94.74% | TD Cowen | Dan Brennan66% | $21 → $20 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 153.16% | Craig-Hallum | Alex Nowark61% | → $26 | Assumes | → Buy | Get Alert |
| 04/30/2024 | Buy Now | 85% | Needham | Mike Matson57% | $24 → $19 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 94.74% | Piper Sandler | David Westenberg59% | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | 85% | Goldman Sachs | Matthew Sykes66% | $17 → $19 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 133.69% | Needham | Mike Matson57% | $21 → $24 | Maintains | Buy | Get Alert |
| 12/29/2023 | Buy Now | 85% | TD Cowen | Dan Brennan66% | $22 → $19 | Maintains | Outperform | Get Alert |
| 12/29/2023 | Buy Now | 104.48% | BTIG | Mark Massaro72% | $25 → $21 | Maintains | Buy | Get Alert |
| 12/28/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2023 | Buy Now | 65.53% | Morgan Stanley | Tejas Savant50% | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 55.79% | Morgan Stanley | Tejas Savant50% | $18 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 65.53% | Goldman Sachs | Matthew Sykes66% | $19 → $17 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 65.53% | Goldman Sachs | Matthew Sykes66% | $19 → $17 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | 75.27% | Piper Sandler | David Westenberg59% | $23 → $18 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 75.27% | Stephens & Co. | Jacob Johnson57% | $16 → $18 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 75.27% | Benchmark | Bruce Jackson42% | $20 → $18 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 75.27% | Morgan Stanley | Tejas Savant50% | $19 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | — | Raymond James | Andrew Cooper54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/10/2023 | Buy Now | 85% | Morgan Stanley | Tejas Savant50% | $18 → $19 | Maintains | Equal-Weight | Get Alert |
| 05/09/2023 | Buy Now | 143.43% | BTIG | Mark Massaro72% | → $25 | Upgrade | Neutral → Buy | Get Alert |
| 05/09/2023 | Buy Now | 114.22% | TD Cowen | Dan Brennan66% | $20 → $22 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | → $21 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | → $21 | Maintains | Buy | Get Alert |
| 04/11/2023 | Buy Now | 65.53% | B of A Securities | Derik De Bruin84% | $18 → $17 | Maintains | Neutral | Get Alert |
| 04/05/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | → $21 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 94.74% | Piper Sandler | David Westenberg59% | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 94.74% | Cowen & Co. | Dan Brennan66% | $14 → $20 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 75.27% | Morgan Stanley | Tejas Savant50% | $17 → $18 | Maintains | Equal-Weight | Get Alert |
| 02/24/2023 | Buy Now | 94.74% | Benchmark | Bruce Jackson42% | → $20 | Upgrade | Hold → Buy | Get Alert |
| 02/24/2023 | Buy Now | 85% | Raymond James | Andrew Cooper54% | $12 → $19 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 104.48% | Needham | Mike Matson57% | $15 → $21 | Maintains | Buy | Get Alert |
| 02/01/2023 | Buy Now | 46.06% | Needham | Mike Matson57% | → $15 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2022 | Buy Now | 75.27% | Piper Sandler | David Westenberg59% | $19 → $18 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | 16.85% | Raymond James | Andrew Cooper54% | $15 → $12 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 65.53% | Morgan Stanley | Tejas Savant50% | $18 → $17 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 46.06% | SVB Leerink | Puneet Souda56% | $12 → $15 | Maintains | Outperform | Get Alert |
| 08/26/2022 | Buy Now | — | Benchmark | Bruce Jackson42% | — | Downgrade | Buy → Hold | Get Alert |
| 08/22/2022 | Buy Now | — | Needham | Mike Matson57% | — | Downgrade | Buy → Hold | Get Alert |
| 08/17/2022 | Buy Now | 85% | Piper Sandler | David Westenberg59% | $13 → $19 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 75.27% | Morgan Stanley | Tejas Savant50% | $19 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 94.74% | Goldman Sachs | Matthew Sykes66% | $18 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | 55.79% | Needham | Mike Matson57% | $19 → $16 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 26.58% | Piper Sandler | David Westenberg59% | → $13 | Initiates | → Overweight | Get Alert |
| 04/28/2022 | Buy Now | 46.06% | Raymond James | Andrew Cooper54% | $18 → $15 | Maintains | Outperform | Get Alert |
| 04/18/2022 | Buy Now | 75.27% | Raymond James | Andrew Cooper54% | $24 → $18 | Maintains | Outperform | Get Alert |
| 04/12/2022 | Buy Now | 162.9% | Morgan Stanley | Tejas Savant50% | $29 → $27 | Maintains | Equal-Weight | Get Alert |
| 03/29/2022 | Buy Now | 75.27% | B of A Securities | Derik De Bruin84% | $25 → $18 | Downgrade | Buy → Neutral | Get Alert |
| 03/29/2022 | Buy Now | 133.69% | Cowen & Co. | Dan Brennan66% | $42 → $24 | Maintains | Outperform | Get Alert |
| 03/29/2022 | Buy Now | 172.64% | BTIG | Mark Massaro72% | $35 → $28 | Maintains | Buy | Get Alert |
| 03/29/2022 | Buy Now | 55.79% | Stephens & Co. | Jacob Johnson57% | $34 → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/29/2022 | Buy Now | 85% | Needham | Mike Matson57% | $29 → $19 | Maintains | Buy | Get Alert |
| 03/29/2022 | Buy Now | 94.74% | SVB Leerink | Puneet Souda56% | $45 → $20 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for NeoGenomics (NEO) stock?
The latest price target for NeoGenomics (NASDAQ:NEO) was reported by Piper Sandler on February 26, 2025. The analyst firm set a price target for $18.00 expecting NEO to rise to within 12 months (a possible 75.27% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeoGenomics (NEO)?
The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by Piper Sandler, and NeoGenomics maintained their overweight rating.
When was the last upgrade for NeoGenomics (NEO)?
The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.
When was the last downgrade for NeoGenomics (NEO)?
The last downgrade for NeoGenomics Inc happened on January 13, 2025 when Benchmark changed their price target from N/A to N/A for NeoGenomics Inc.
When is the next analyst rating going to be posted or updated for NeoGenomics (NEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.
Is the Analyst Rating NeoGenomics (NEO) correct?
While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a maintained with a price target of $21.00 to $18.00. The current price NeoGenomics (NEO) is trading at is $10.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.